

ZURICH BIOTECH+

+ Peptide Researcher's Starter Guide

Essential knowledge for researchers beginning peptide investigation. Purity standards, handling protocols, safety systems, and a complete reference glossary.

RESEARCH RESOURCE • ZURICH BIOTECH+ • 2026

CHAPTERS

4

CLINICAL REFERENCES

28

READING TIME

25 min

+ Contents

1. Understanding Peptide Purity Grades

1.1 Research vs. Cosmetic vs. Pharmaceutical Grade

1.2 Reading a Certificate of Analysis

1.3 Purity Thresholds and When You Need Each

2. Handling and Reconstitution Protocols

2.1 Lyophilized Peptides: Solvent Selection

2.2 Step-by-Step Reconstitution

2.3 Common Mistakes That Destroy Peptides

2.4 Storage Guidelines

3. Research Safety Essentials

3.1 Personal Protective Equipment

3.2 Biosafety Cabinet Best Practices

3.3 Pre-Experiment Safety Checklist

4. Glossary of Essential Terms

Clinical References

+ Understanding Peptide Purity Grades

Not all peptides are created equal. The grade of peptide you select determines its suitability for specific research applications, and misunderstanding these distinctions is one of the most common sources of experimental failure in peptide research.

+ Research vs. Cosmetic vs. Pharmaceutical Grade

The peptide industry recognizes three primary quality tiers, each governed by different manufacturing standards, analytical requirements, and intended use cases. Selecting the appropriate grade is not merely a budget decision — it directly impacts experimental validity and reproducibility.

ATTRIBUTE	RESEARCH GRADE	COSMETIC GRADE	PHARMACEUTICAL (GMP)
Purity Standard	>95% typical	Variable (85-95%)	>98%, often >99%
Manufacturing	ISO-monitored	Unregulated	Full cGMP compliance
Analytical Testing	HPLC, MS	Limited	HPLC, MS, NMR, EA, endotoxin
Documentation	COA provided	Often absent	Complete CMC dossier
Intended Use	<i>In vitro</i> research	Topical formulation	Human clinical trials
Endotoxin Testing	Available on request	Rarely performed	Mandatory, <0.5 EU/mg
Batch Consistency	Lot-to-lot COA	Variable	Validated, statistical release

ZURICH BIOTECH STANDARD

All Zurich Biotech+ peptides are manufactured at research grade minimum >98% purity, with full HPLC and MS characterization. Each vial ships with a verifiable Certificate of Analysis specific to its production batch.

+ Reading a Certificate of Analysis

The Certificate of Analysis (COA) is the single most important document accompanying any peptide shipment. A properly constructed COA provides quantitative evidence of identity, purity, and quality. Researchers should review it before using any peptide in experimental work.

High-Performance Liquid Chromatography (HPLC) data demonstrates chromatographic purity by separating the target peptide from related substances — including deletion sequences, truncated variants, and side products — based on hydrophobicity. The peak area percentage of the target peptide relative to all detected peaks provides the purity value. Reverse-phase HPLC (RP-HPLC) with UV detection at 214 nm or 220 nm is the standard methodology for peptide purity assessment.[1]

Mass Spectrometry (MS) confirms molecular identity by comparing the measured molecular weight against the theoretical value calculated from the amino acid sequence. Electrospray ionization (ESI-MS) or matrix-assisted laser desorption/ionization (MALDI-MS) are standard techniques. The observed mass should be within 1 Da of the theoretical molecular weight for sequences under 5 kDa.

COA PARAMETER	WHAT IT TELLS YOU	ACCEPTABLE RANGE
Chromatographic Purity (HPLC)	Percentage of target vs. impurities	>95% for research; >98% for precise work
Molecular Weight (MS)	Confirms correct sequence	Within 1.0 Da of theoretical
Appearance	Physical form of lyophilizate	White to off-white powder
Solubility	Verified dissolution	Clear solution in specified solvent
Peptide Content	Net peptide vs. counterion	70-90% typical (balance is TFA/water)

RED FLAGS ON A COA

No mass spectrometry data, missing batch number, HPLC purity <90%, no testing date, no analyst signature, mismatch between stated sequence and molecular weight — any of these should prompt immediate quality inquiry before use.

+ Purity Thresholds and When You Need Each

The purity requirement for any given experiment depends on the sensitivity of the assay system and the potential for impurities to confound results. A purity level adequate for cell culture screening may be insufficient for structural biology or *in vivo* pharmacology.

APPLICATION CATEGORY	MINIMUM PURITY	RATIONALE
Preliminary screening, binding assays	>95%	Impurities unlikely to interfere with primary readout
Cell culture, <i>in vitro</i> pharmacology	>97%	Certain impurities may trigger off-target cellular responses
Mechanistic studies, SPR, NMR	>98%	Impurities can confound structural and kinetic measurements
<i>In vivo</i> research (animal models)	>98%, endotoxin-tested	Biological contaminants can provoke immune responses
Reference standard, formulation work	>99%	Regulatory and patent applications require highest grade

+ Handling and Reconstitution Protocols

Lyophilized peptides are stable and robust when stored properly, but they become vulnerable the moment they encounter solvent. Correct reconstitution technique determines whether your peptide remains active throughout the experimental timeline.

+ Lyophilized Peptides: Solvent Selection

The choice of reconstitution solvent depends on peptide sequence characteristics, particularly hydrophobicity and charge profile. Using the wrong solvent can result in incomplete dissolution, aggregation, or immediate chemical degradation.

Bacteriostatic water (0.9% benzyl alcohol) is the standard reconstitution vehicle for most peptides. The weak bacteriostatic effect of benzyl alcohol helps prevent microbial growth in multi-dose vials without interfering with most biological assays. It is suitable for the majority of hydrophilic and moderately hydrophobic peptides.

Sterile water for injection should be used when benzyl alcohol may interfere with the experimental system — for example, in certain cell culture applications or when the peptide will be used at very high dilutions where even trace organics may matter.

Acetic acid solutions (0.1-10% glacial acetic acid in sterile water) are necessary for highly hydrophobic or basic peptides that resist dissolution in water alone. Acetic acid protonates acidic side chains, increasing solubility. Start with a low concentration and increase only if required.

PEPTIDE CHARACTERISTICS	RECOMMENDED SOLVENT
Short (<15 residues), hydrophilic	Bacteriostatic water
Moderate length, balanced charge	Bacteriostatic water or sterile saline
Basic (multiple Lys, Arg, His residues)	0.1-1% acetic acid
Highly hydrophobic	10% acetic acid or DMSO (then dilute)
Contains Cys (disulfide bond potential)	Acidic conditions; avoid neutral/basic pH
Contains Trp, Met (oxidation-sensitive)	Acidic buffer; degassed solvents preferred

+ Step-by-Step Reconstitution

- 1 Inspect the vial.** Confirm the label matches your COA. Examine the lyophilized cake — it should appear as a uniform white to off-white powder or compact.
- 2 Allow temperature equilibration.** Bring the peptide vial and solvent to room temperature (18-25 degrees C) before opening. Do not reconstitute cold — condensation introduces moisture prematurely.
- 3 Calculate target concentration.** Determine your desired working concentration based on experimental requirements. Most researchers reconstitute at 1-10 mg/mL, then dilute to working concentration.
- 4 Introduce solvent slowly.** Angle the vial and run the solvent down the interior wall, not directly onto the lyophilized cake. This prevents mechanical stress and foaming.
- 5 Dissolve without agitation.** Allow the peptide to dissolve undisturbed for several minutes. Do not vortex, shake vigorously, or sonicate — mechanical stress can denature peptides and promote aggregation.[2]
- 6 Gentle rotation if needed.** If the peptide has not fully dissolved after 10 minutes of undisturbed standing, apply gentle rotation or inversion — never vigorous shaking.
- 7 Inspect and aliquot.** Verify the solution is clear and free of visible particles. Immediately aliquot into single-use vials if the peptide will not be consumed within 1-2 weeks.

CRITICAL WARNING

Never reconstitute a peptide and leave it at room temperature for extended periods. Once in solution, peptides become susceptible to hydrolysis, oxidation, and microbial contamination. The clock starts the moment solvent meets peptide.

+ Common Mistakes That Destroy Peptides

MISTAKE	WHY IT MATTERS	CONSEQUENCE
Vortexing or vigorous shaking	Mechanical shear forces denature peptides; introduces air (oxidation)	Aggregation, loss of bioactivity
Reconstituting with warm solvent	Temperature shock alters folding kinetics	Irreversible aggregation
Direct solvent stream onto cake	Localized high concentration causes precipitation	Incomplete dissolution
Using tap or unsterile water	Microbial contamination, pyrogens, metal ions	Degradation, invalid results
Storing reconstituted at 4C >14 days	Hydrolysis and oxidation proceed even cold	Progressive loss of potency
Repeated freeze-thaw cycles	Ice crystal formation disrupts structure	Aggregation, precipitation
Incorrect pH selection	Peptides have narrow pH stability windows	Chemical degradation

+ Storage Guidelines

Proper storage extends peptide stability from weeks to years. Lyophilized peptides stored at -20 degrees C in a desiccated environment remain stable for 24-36 months. Once reconstituted, the stability window narrows considerably.

STATE	STORAGE TEMPERATURE	EXPECTED STABILITY	BEST PRACTICES
Lyophilized powder	-20 degrees C, desiccated	24-36 months	Avoid humidity; use sealed container with desiccant
Lyophilized powder	2-8 degrees C, desiccated	12-18 months	Short-term storage; monitor for moisture
Reconstituted solution	2-8 degrees C	7-14 days	Aliquot if possible; limit access to reduce contamination risk
Aliquoted, frozen	-20 degrees C	3-6 months	Single-use aliquots; no refreezing
Aliquoted, frozen	-80 degrees C	6-12 months	Optimal for long-term preservation of sensitive peptides

Stability Reference: Peptide stability is influenced by sequence composition, solvent, pH, temperature, and exposure to oxygen. Peptides containing methionine, cysteine, and tryptophan residues show enhanced susceptibility to oxidation and require particular care in storage environment and handling.^[2]

+ Research Safety Essentials

Peptide research materials are intended for laboratory use only. Proper safety protocols protect the researcher, preserve experimental integrity, and maintain regulatory compliance. These standards represent minimum requirements — institutional policies may impose additional controls.

+ Personal Protective Equipment

All peptide handling requires standard laboratory PPE as a baseline. Additional protective measures apply when working with concentrated stock solutions, biological matrices, or novel/uncharacterized sequences.

- **Nitrile gloves** — Double-gloving recommended for concentrated stock handling or when skin contact risk is elevated. Change gloves immediately if contamination is suspected.
- **Laboratory coat** — Knee-length, closed-front. Dedicated to peptide work if possible. Remove before leaving the laboratory.
- **Eye protection** — Safety glasses minimum; splash goggles when preparing solutions or working with pressurized containers.
- **Closed-toe shoes** — Non-negotiable in any active laboratory environment.
- **Respiratory protection** — N95 or P2 mask when handling lyophilized powder outside a containment device; powder aerosolization is the primary inhalation risk.

+ Biosafety Cabinet Best Practices

Peptide reconstitution and aliquoting should be performed in a Class II biological safety cabinet (BSC) or laminar flow hood. This protects both the researcher (from powder aerosols) and the peptide (from environmental contamination).

- Certify cabinet airflow annually; verify sash position before each use.
- Disinfect all surfaces with 70% ethanol or appropriate disinfectant before and after use.
- Position materials to maintain clear air grille — never block front or rear grilles.
- Allow cabinet to run for 15 minutes before beginning work to purge particulates.
- Work in the center of the cabinet, 10-15 cm from the front edge — the optimal clean air zone.
- Dispose of all consumables as biohazardous waste per institutional policy.

+ Pre-Experiment Safety Checklist

CATEGORY	CHECK	ITEM
Personal Protection	<input type="checkbox"/>	Nitrile gloves donned; no tears or degradation
	<input type="checkbox"/>	Laboratory coat fastened
	<input type="checkbox"/>	Eye protection in place
	<input type="checkbox"/>	Long hair tied back; no loose jewelry
Work Environment	<input type="checkbox"/>	BSC airflow verified; sash at correct height
	<input type="checkbox"/>	Work surface disinfected
	<input type="checkbox"/>	Sharps container accessible
	<input type="checkbox"/>	Emergency eyewash station confirmed functional
Materials Verification	<input type="checkbox"/>	Peptide label matches COA and order record
	<input type="checkbox"/>	COA reviewed; purity and identity confirmed
	<input type="checkbox"/>	Solvent within expiry date; sterile and appropriate
	<input type="checkbox"/>	Syringes, vials, and consumables sterile
Documentation	<input type="checkbox"/>	Experiment number assigned and recorded
	<input type="checkbox"/>	Lot number logged in laboratory notebook
	<input type="checkbox"/>	Colleague notified of solo work (if applicable)

+ Glossary of Essential Terms

The peptide research field carries specialized terminology from biochemistry, analytical chemistry, and pharmacology. This glossary defines the terms researchers encounter most frequently when working with synthetic peptides.

Amino Acid	The fundamental building block of peptides and proteins. Twenty standard amino acids are encoded by DNA, each with a distinct side chain conferring unique chemical properties.
Amphipathic	A peptide or amino acid sequence containing both hydrophilic (water-attracting) and hydrophobic (water-repelling) regions.
Bacteriostatic Water	Sterile water containing 0.9% benzyl alcohol as a preservative. The standard reconstitution solvent for research peptides.
Chromatographic Purity	The percentage of the target peptide relative to all UV-absorbing species detected by HPLC analysis, as reported on the COA.
COA	Certificate of Analysis. The document accompanying a peptide batch that reports analytical results including purity, identity, and physical properties.
Counterion	The ionic species paired with a charged peptide to maintain electrical neutrality. Most commonly trifluoroacetate (TFA) from the cleavage and purification process.
Disulfide Bridge	A covalent bond formed between two cysteine residues, creating a sulfur-sulfur linkage that stabilizes peptide tertiary structure.
Half-life	The time required for the concentration of a peptide to decrease by 50% under specified conditions. In pharmacology, refers to plasma clearance; in storage, refers to chemical stability.
HPLC	High-Performance Liquid Chromatography. The primary analytical technique for peptide purity determination, separation, and preparative purification.[1]
Hydrophilicity	The tendency of a molecule to interact with water. Hydrophilic peptides dissolve readily in aqueous solvents.
Hydrophobicity	The tendency of a molecule to repel water. Hydrophobic peptides resist aqueous dissolution and may require organic co-solvents.
Lyophilization	Freeze-drying. The process of removing water from a frozen peptide solution under vacuum, producing a stable dry powder (cake) for long-term storage.

MALDI-MS	Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry. A soft ionization technique for measuring peptide molecular weight, often used for identity confirmation.
Mass Spectrometry (MS)	An analytical technique that measures the mass-to-charge ratio of ions, providing molecular weight data that confirms peptide identity.
Peptide Content	The percentage of net peptide in the product versus counterions (typically TFA) and residual water. Research peptides typically contain 70-90% net peptide by weight.
Reconstitution	The process of dissolving a lyophilized peptide in an appropriate solvent to prepare a stock solution at a defined concentration.
RP-HPLC	Reverse-Phase High-Performance Liquid Chromatography. The most widely used HPLC mode for peptide separation, utilizing a hydrophobic stationary phase and aqueous-organic mobile phase.[1]
SPPS	Solid-Phase Peptide Synthesis. The primary method for manufacturing research peptides, wherein amino acids are added stepwise to a growing chain attached to an insoluble resin support.[3]
TFA	Trifluoroacetic acid. A strong organic acid used in peptide cleavage from synthesis resin and as a mobile phase modifier in RP-HPLC. Remains as a counterion in the final product.
Truncated Sequence	A peptide impurity resulting from incomplete coupling during synthesis, missing one or more amino acids from the intended sequence.

+ Clinical References

1. Mant CT, Hodges RS. HPLC analysis and purification of peptides. *Methods in Molecular Biology*. 2020;2141:155-189. doi:10.1007/978-1-0716-0524-2_8. PMID: PMC7119934.
2. Jocelyn PC. Chemical reduction of disulfides. *Methods in Enzymology*. 1987;143:246-256. doi:10.1016/S0076-6879(87)43035-8.
3. Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. *Journal of the American Chemical Society*. 1963;85(14):2149-2154. doi:10.1021/ja00897a025.
4. Carpino LA, Han GY. The 9-fluorenylmethoxycarbonyl amino-protecting group. *Journal of the Organic Chemistry*. 1972;37(22):3404-3409.
5. Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. *International Journal of Peptide and Protein Research*. 1990;35(3):161-214. doi:10.1111/j.1399-3011.1990.tb01768.x.
6. Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. *Current Pharmaceutical Design*. 2018;24(18):1972-1989. doi:10.2174/1381612824666180712110447.
7. Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat: gastric pentadecapeptide BPC 157. *Journal of Orthopaedic Research*. 2006;24(5):1109-1117. doi:10.1002/jor.20089.
8. Krivic A, Anic T, Seiwerth S, et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. *Journal of Orthopaedic Research*. 2006;24(5):982-989. doi:10.1002/jor.20096.
9. Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva). *Inflammopharmacology*. 2006;14(5-6):214-221. doi:10.1007/s10787-006-1531-7.
10. Pickart L, Thayer L, Thaler MM. A synthetic tripeptide which increases survival of normal liver cells, and stimulates growth in hepatoma cells. *Biochemical and Biophysical Research Communications*. 1973;54(2):562-566. doi:10.1016/0006-291X(73)91464-4.
11. Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. *Aging and Disease*. 2012;3(5):368-378. PMID: PMC3494599.
12. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. *BioDrugs*. 2015;7(1):5. doi:10.1186/s13287-015-0050-1.
13. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. *Bulletin of Experimental Biology and Medicine*. 2003;135(6):590-592. doi:10.1023/A:1025493703648.
14. Anisimov VN, Khavinson VKh, Mikhalski AI, et al. Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice. *Mechanisms of Ageing and Development*. 2001;122(1):41-68. doi:10.1016/S0047-6374(00)00184-6.
15. Anisimov VN, Khavinson VKh, Popovich IG, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. *Biogerontology*. 2003;4(4):193-202. doi:10.1023/A:1025114230714.
16. Rosenfeld SV, Togo EF, Mikheev VS, et al. Effect of epithalon on the incidence of chromosome aberrations in senescence-accelerated mice. *Bulletin of Experimental Biology and Medicine*. 2002;133(3):274-276. doi:10.1023/A:1015899003974.

17. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *New England Journal of Medicine*. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563. (SELECT Trial)
18. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. *JAMA*. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224. (STEP 4 Trial)
19. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. *New England Journal of Medicine*. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. (STEP 1 Trial)
20. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. *The Lancet*. 2021;398(10295):143-155. doi:10.1016/S0140-6736(21)01324-6.
21. Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. *The Lancet*. 2021;398(10300):583-598. doi:10.1016/S0140-6736(21)01245-0.
22. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. *European Journal of Endocrinology*. 1998;139(5):552-561. doi:10.1530/eje.0.1390552.
23. Göke R, Fehmman HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. *Journal of Biological Chemistry*. 1993;268(26):19650-19655. doi:10.1016/S0021-9258(19)36469-0.
24. Drucker DJ. Enhancing the action of incretin hormones: a new whey forward? *Endocrinology*. 2006;147(7):3171-3172. doi:10.1210/en.2006-0449.
25. Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. *Journal of Medicinal Chemistry*. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726.
26. Friedrichsen HN, Breitschaft A, Tadayon S, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, gastric emptying, and glycemic responses in subjects with obesity. *Diabetes, Obesity and Metabolism*. 2021;23(3):754-762. doi:10.1111/dom.14280.
27. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. *The Lancet Diabetes & Endocrinology*. 2021;9(10):653-662. doi:10.1016/S2213-8587(21)00203-5.
28. US Food and Drug Administration. *Guidance for Industry: Nonclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals*. FDA Center for Drug Evaluation and Research; 1997. S6 guidance.